These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24939425)

  • 1. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.
    Cegla J; Troke RC; Jones B; Tharakan G; Kenkre J; McCullough KA; Lim CT; Parvizi N; Hussein M; Chambers ES; Minnion J; Cuenco J; Ghatei MA; Meeran K; Tan TM; Bloom SR
    Diabetes; 2014 Nov; 63(11):3711-20. PubMed ID: 24939425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
    Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
    Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.
    Tan TM; Field BC; McCullough KA; Troke RC; Chambers ES; Salem V; Gonzalez Maffe J; Baynes KC; De Silva A; Viardot A; Alsafi A; Frost GS; Ghatei MA; Bloom SR
    Diabetes; 2013 Apr; 62(4):1131-8. PubMed ID: 23248172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.
    Bagger JI; Holst JJ; Hartmann B; Andersen B; Knop FK; Vilsbøll T
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4541-52. PubMed ID: 26445112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala.
    Parker JA; McCullough KA; Field BC; Minnion JS; Martin NM; Ghatei MA; Bloom SR
    Int J Obes (Lond); 2013 Oct; 37(10):1391-8. PubMed ID: 23337772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
    Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.
    Gutzwiller JP; Degen L; Matzinger D; Prestin S; Beglinger C
    Am J Physiol Regul Integr Comp Physiol; 2004 Sep; 287(3):R562-7. PubMed ID: 15105167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
    Gutzwiller JP; Drewe J; Göke B; Schmidt H; Rohrer B; Lareida J; Beglinger C
    Am J Physiol; 1999 May; 276(5):R1541-4. PubMed ID: 10233049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
    Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
    Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Drewe J; Beglinger C
    Am J Clin Nutr; 2010 Oct; 92(4):810-7. PubMed ID: 20720259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
    Chelikani PK; Haver AC; Reidelberger RD
    Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides.
    Rigamonti AE; Casnici C; Marelli O; De Col A; Tamini S; Lucchetti E; Tringali G; De Micheli R; Abbruzzese L; Bortolotti M; Cella SG; Sartorio A
    Nutr Res; 2018 Apr; 52():71-79. PubMed ID: 29530622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers.
    Tan T; Behary P; Tharakan G; Minnion J; Al-Najim W; Albrechtsen NJW; Holst JJ; Bloom SR
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2364-2372. PubMed ID: 28379519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1: a potent regulator of food intake in humans.
    Gutzwiller JP; Göke B; Drewe J; Hildebrand P; Ketterer S; Handschin D; Winterhalder R; Conen D; Beglinger C
    Gut; 1999 Jan; 44(1):81-6. PubMed ID: 9862830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
    Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
    Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.